Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer-Reference-Cited by-同舟云学术

Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer

Published:2017-08-08 Issue:10 Volume:11 Page:1413-1429
ISSN:1574-7891
Container-title:Molecular Oncology
language:en
Short-container-title:Mol Oncol

Author:

Malgerud Linnéa¹²^ORCID,Lindberg Johan³,Wirta Valtteri⁴,Gustafsson-Liljefors Maria⁵,Karimi Masoud⁵,Moro Carlos Fernández⁶,Stecker Katrin⁷,Picker Alexander⁷,Huelsewig Carolin⁷,Stein Martin⁷,Bohnert Regina⁷,Del Chiaro Marco¹²,Haas Stephan L.¹,Heuchel Rainer L.²,Permert Johan⁸,Maeurer Markus J.⁹,Brock Stephan⁷,Verbeke Caroline S.⁶,Engstrand Lars⁴,Jackson David B.⁷,Grönberg Henrik³,Löhr Johannes-Matthias¹²

Affiliation:

1. Center for Digestive Diseases; Karolinska University Hospital; Stockholm Sweden

2. Department of Clinical Sciences; Intervention and Technology (CLINTEC); Karolinska Institutet; Stockholm Sweden

3. Department of Medical Epidemiology & Biostatistics (MEB); Karolinska Institutet; Stockholm Sweden

4. Science for Life Laboratory; Department of Microbiology, Tumor and Cell Biology (MTC); Karolinska Institutet; Stockholm Sweden

5. Department of Oncology at Radiumhemmet; Karolinska University Hospital; Stockholm Sweden

6. Department of Pathology; Karolinska University Hospital; Stockholm Sweden

7. Molecular Health GmbH; Heidelberg Germany

8. Innovation Office; Karolinska University Hospital; Stockholm Sweden

9. Department of Laboratory Medicine (LABMED); Karolinska Institutet; Stockholm Sweden

Publisher

Wiley

Subject

Cancer Research,Genetics,Molecular Medicine,General Medicine,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/1878-0261.12108/fullpdf

Reference82 articles.

1. Aurora kinase inhibitors: current status and outlook;Bavetsias;Front Oncol,2015

2. Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer;Bendell;Ann Oncol,2015

3. Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification;Bhaw-Luximon;J Cancer Res Clin Oncol,2016

4. Pancreatic adenocarcinoma;Bond-Smith;BMJ,2012

5. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer;Bramhall;Br J Cancer,2002

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding the Genetic Landscape of Pancreatic Ductal Adenocarcinoma to Support Personalized Medicine: A Systematic Review;Cancers;2023-12-21

2. The FIRST-Dx Study Takes Steps Toward Personalized Cancer Therapy;JAMA Network Open;2023-07-17

3. Bioinformatics and Biostatistics in Precision Medicine;Oncology: Genomics, Precision Medicine and Therapeutic Targets;2023

4. CLCA4 and MS4A12 as the significant gene biomarkers of primary colorectal cancer;Bioscience Reports;2020-08

5. Islets and pancreatic ductal adenocarcinoma – An opportunity for translational research from the ‘Bench to the Bedside’;Pancreatology;2020-04